Overview

04/26/16 at 5:00 PM ET
MannKind to Discuss U.S. Commercialization Update of Afrezza
Podcast Listen to webcast   6.6 MB   Add to Briefcase

MannKind Corporation (Nasdaq and TASE: MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.

AFREZZA® (pronounced uh-FREZZ-uh), approved in 2014 by the U.S. Food and Drug Administration is a rapid-acting inhaled insulin therapy indicated to improve glycemic control in adults with diabetes. Taken at the start of a meal using a specially designed inhaler, Afrezza dissolves rapidly upon inhalation to the deep lung and delivers insulin quickly to the bloodstream. Peak insulin levels are achieved within 12 to 15 minutes of use and help to control post-meal blood sugar spikes that affect HbA1C levels.

AFREZZA utilizes our proprietary Technosphere® formulation technology , which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded.  We believe Technosphere represents a versatile drug delivery platform that may allow pulmonary administration of certain drugs that currently require administration by injection, such as GLP-1. Pulmonary administration provides convenience for the patient and we believe a major advantage of drugs inhaled as Technosphere formulations is that they have been shown to be absorbed very rapidly into the arterial circulation, essentially mimicking intra-arterial administration. MannKind is also developing other inhalation technologies, including an innovative line of patient-focused, breath-activated, dry powder inhalers and inhalation profiling to characterize patient inhalation.

Stock price graph
     

View all »   RSSRecent Releases

08/25/16
Securities Class Action Against MannKind Dismissed

08/08/16
MannKind Corporation Reports 2016 Second Quarter Financial Results

MNKD

Exchange:
NASDAQ GM and TASE(US Dollar)

Price: 0.79

Change: 0.05 (5.613%)

Volume: 6,143,482

Data as of
08/26/2016 04:00 PM ET .
Minimum 20 minute delay.

Refresh Quote >

Locations

Learn more about MannKind's offices in the United States

Learn More